Ligelizumab improves sleep interference and disease burden in patients with chronic spontaneous urticaria
Sign Up to like & getrecommendations! Published in 2022 at "Clinical and Translational Allergy"
DOI: 10.1002/clt2.12121
Abstract: Abstract Background Chronic spontaneous urticaria (CSU) negatively impacts patients' sleep, thereby reducing healthârelated quality of life (HRQoL). Half of patients with inadequately controlled CSU report sleep interference often or every night, which can lead to… read more here.
Keywords: placebo; chronic spontaneous; ligelizumab 240; treatment ... See more keywords